-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$6.25557.89% Upside
Prelude Therapeutics Incorporated Frequently Asked Questions
-
What analysts cover Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated has been rated by research analysts at H.C. Wainwright, Barclays, JMP Securities, Morgan Stanley in the past 90 days.